These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19396596)

  • 1. Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.
    Lesinski GB; Benninger K; Kreiner M; Quimper M; Young G; Carson WE
    Cancer Immunol Immunother; 2009 Dec; 58(12):2031-7. PubMed ID: 19396596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.
    Markowitz J; Luedke EA; Grignol VP; Hade EM; Paul BK; Mundy-Bosse BL; Brooks TR; Dao TV; Kondalasula SV; Lesinski GB; Olencki T; Kendra KL; Carson WE
    J Immunother; 2014 Jan; 37(1):55-62. PubMed ID: 24316557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
    Ying M; Zhou X; Zhong L; Lin N; Jing H; Luo P; Yang X; Song H; Yang B; He Q
    Mol Cancer Ther; 2013 Feb; 12(2):195-206. PubMed ID: 23243061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
    Amiri KI; Horton LW; LaFleur BJ; Sosman JA; Richmond A
    Cancer Res; 2004 Jul; 64(14):4912-8. PubMed ID: 15256463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
    Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
    Surgery; 2006 Aug; 140(2):297-306. PubMed ID: 16904983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.
    Freudlsperger C; Thies A; Pfüller U; Schumacher U
    Anticancer Res; 2007; 27(1A):207-13. PubMed ID: 17352234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells.
    Kao C; Chao A; Tsai CL; Lin CY; Chuang WC; Chen HW; Yen TC; Wang TH; Lai CH; Wang HS
    Cell Death Dis; 2013 Feb; 4(2):e512. PubMed ID: 23449448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
    Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
    Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.
    Steg AD; Burke MR; Amm HM; Katre AA; Dobbin ZC; Jeong DH; Landen CN
    Oncotarget; 2014 Aug; 5(16):7065-80. PubMed ID: 25216523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma.
    Lesinski GB; Badgwell B; Zimmerer J; Crespin T; Hu Y; Abood G; Carson WE
    J Immunol; 2004 Jun; 172(12):7368-76. PubMed ID: 15187113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
    Lesinski GB; Trefry J; Brasdovich M; Kondadasula SV; Sackey K; Zimmerer JM; Chaudhury AR; Yu L; Zhang X; Crespin TR; Walker MJ; Carson WE
    Clin Cancer Res; 2007 Sep; 13(17):5010-9. PubMed ID: 17785551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines.
    Kovarik A; Fojtova M; Boudny V; Adamkova L; Lauerova L; Kovarik J
    Melanoma Res; 2005 Dec; 15(6):481-8. PubMed ID: 16314732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
    Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
    Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the eIF2alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells.
    Yerlikaya A; DoKudur H
    Mol Biol (Mosk); 2010; 44(5):859-66. PubMed ID: 21090173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
    Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
    Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis.
    Lesinski GB; Raig ET; Guenterberg K; Brown L; Go MR; Shah NN; Lewis A; Quimper M; Hade E; Young G; Chaudhury AR; Ladner KJ; Guttridge DC; Bouchard P; Carson WE
    Cancer Res; 2008 Oct; 68(20):8351-60. PubMed ID: 18922907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells.
    Lesinski GB; Zimmerer JM; Kreiner M; Trefry J; Bill MA; Young GS; Becknell B; Carson WE
    BMC Cancer; 2010 Apr; 10():142. PubMed ID: 20398276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
    Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
    J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
    Guenterberg KD; Grignol VP; Raig ET; Zimmerer JM; Chan AN; Blaskovits FM; Young GS; Nuovo GJ; Mundy BL; Lesinski GB; Carson WE
    Mol Cancer Ther; 2010 Feb; 9(2):510-20. PubMed ID: 20103601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
    Su Y; Amiri KI; Horton LW; Yu Y; Ayers GD; Koehler E; Kelley MC; Puzanov I; Richmond A; Sosman JA
    Clin Cancer Res; 2010 Jan; 16(1):348-57. PubMed ID: 20028756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.